Page last updated: 2024-11-05

tetramethylsilane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6396
CHEMBL ID68073
CHEBI ID85361
MeSH IDM0197991

Synonyms (53)

Synonym
silicon, tetramethyl-
nsc5210
nsc-5210
tetramethylsilane ,
silane, tetramethyl-
75-76-3
tetramethylsilicane
inchi=1/c4h12si/c1-5(2,3)4/h1-4h
tetramethylsilane, electronic grade, >=99.99% trace metals basis
tetramethyl silane
nsc 5210
einecs 200-899-1
un2749
tetramethylsilane, >=99.0% (gc)
bdbm50088357
chebi:85361 ,
CHEMBL68073 ,
tetramethyl-silane
tetramethylsilane [un2749] [flammable liquid]
T0154
NCGC00248490-01
AKOS009156489
tox21_200011
cas-75-76-3
dtxcid206423
NCGC00257565-01
dtxsid9026423 ,
hsdb 7759
ec 200-899-1
41y0rbg14q ,
unii-41y0rbg14q
FT-0631316
S16225
tetramethylsilane [mi]
S2274
tetramethylsilane (tms)
(ch3)4si
ct2050
si(ch3)4
un 2749
me4si
sime4
STL453400
F0001-1903
tetramethylsilane, analytical standard, for nmr spectroscopy, acs reagent
tetramethylsilane, produced by wacker chemie ag, burghausen, germany, >=99.0% (gc)
mfcd00008274
tetramethylsilane, acs reagent, nmr grade, >=99.9%
Q415329
tetra-methyl silane
tetra-methylsilane
tetramethylsilane,nmr grade(99.9% min)
PD127636
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
NMR chemical shift reference compoundAny compound that produces a peak used to reference an NMR spectrum during data pre-processing.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organosilicon compoundAn organosilicon compound is a compound containing at least one carbon-silicon bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency33.89770.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.16410.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency0.20660.000714.592883.7951AID1259369
pregnane X nuclear receptorHomo sapiens (human)Potency51.88910.005428.02631,258.9301AID1346982
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrase Human immunodeficiency virus 1IC50 (µMol)11.00000.00051.544310.0000AID91425; AID91426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID91426Tested for inhibition of HIV-1 integrase, under 1 uM for the strand transfer2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
AID91425Inhibition of HIV-1 integrase, under 1 uM for the 3''-preprocessing2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Developing a dynamic pharmacophore model for HIV-1 integrase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (24.24)18.2507
2000's16 (48.48)29.6817
2010's9 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.52 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index84.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]